SCHEMBL6748702

SCHEMBL6748702

CC(C)(C)c1cc(C#N)cc(O)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.47
ALB P02768 2/20 0.47
CA2 P00918 3/20 0.45
CA1 P00915 2/20 0.45
SMN1; SMN2 Q16637 6/20 0.44
ALDH1A1 P00352 5/20 0.44
ALOX15 P16050 5/20 0.44
MAPT P10636 5/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
CYP1A2 P05177 4/20 0.44
CYP2C9 P11712 4/20 0.44
HSD17B10 Q99714 4/20 0.44
LMNA P02545 3/20 0.44
CYP2C19 P33261 3/20 0.44
CYP3A4 P08684 3/20 0.44
TSHR P16473 3/20 0.44
BLM P54132 3/20 0.44
RGS12 O14924 2/20 0.44
GMNN O75496 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3578249 0.90 CA2 (0.56) TTRALBCA2CA1SMN1; SMN2
SCHEMBL10766961 0.81 MEN1 (0.64) TTRALBCA2CA1SMN1; SMN2
SCHEMBL10765819 0.81 TTR (0.70) TTRALBCA2CA1SMN1; SMN2
SCHEMBL6888576 0.78 MEN1 (0.50) TTRALBCA2CA1SMN1; SMN2
SCHEMBL4168959 0.78 MEN1 (0.56) TTRALBCA2CA1SMN1; SMN2
SCHEMBL5368308 0.78 ALDH1A1 (0.57) TTRALBCA2SMN1; SMN2ALDH1A1
SCHEMBL29437966 0.78 ALDH1A1 (0.57) TTRALBCA2SMN1; SMN2ALDH1A1
SCHEMBL2154631 0.76 KIF11 (0.40) TTRALBCA2CA1SMN1; SMN2
SCHEMBL18587383 0.76 ALDH1A1 (0.48) TTRALBCA2SMN1; SMN2ALDH1A1
SCHEMBL2153658 0.74 KIF11 (0.39) TTRALBCA2CA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040987-B2 Penam derivatives for treating bacterial infections TENNOR THERAPEUTICS LIMITED (CN) 2021-06-22 US disclosed
US-6693062-B2 LIGHT INSENSITIVE ORGANIC SILVER SALTS, REDUCING AGENTS AND 1,2-DIHYDROXYBENZENE DERIVATIVE AGFA-GEVAERT (BE) 2004-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040987-B2 Penam derivatives for treating bacterial infections BPGM, BLVRB, PREP TTR 3245/4885ALB 525/4885CA2 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.